Next Meetings

May 31, 2017

Kaiser Permanente Center for Total Health
700 2nd St NE, Washington, DC 20002
Washington, DC

ICER is hosting a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit will include discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.

Registration for the in-person meeting is at capacity, but a webcast will be available (registration link below).

Process for Public Comment
A Briefing Paper posted on May 10, 2017 (white paper below) will inform the discussion during the pricing summit. Following the meeting, ICER will produce a Final Meeting Report and Proposed Framework Changes document outlining modifications to its assessment process when applied to treatments for rare conditions. This document will be open for public comment for 60 days. Dates reflected below are tentative and subject to change.

In addition to the Briefing Paper, the following academic papers may serve as useful pre-reading for the Summit:
Tordrup D TV, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs. 2014;1(3):83-95.
Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM : Monthly Journal of the Association of Physicians. 2005;98(11):829-836.

Register or Register for the Live Webcast

June 30, 2017

The California Endowment Los Angeles Conference Center
1000 N. Alameda St.
Los Angeles, CA, 90012

The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.

Register or Register for the Live Webcast

Abuse-Deterrent Opioids

New England CEPAC

ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.

Register or Register for the Live Webcast

Ovarian Cancer

Midwest CEPAC
September 14, 2017 10AM-4PM (CT)

Midwest, TBD

The Midwest CEPAC will convene to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.


October 19, 2017 TBD

California TBD

ICER will review evidence on the comparative clinical effectiveness and value of certain cognitive and mind-body interventions for chronic low back and neck pain.


Tardive Dyskinesia

New England CEPAC
December 5, 2017 10am-4pm ET

past Meetings

Jun 2016
CTAF

Diabetes Prevention Programs

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.


Feb 2016
CTAF

Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes

The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.